ResMed Inc.
RMD
$224.09
+0.56%
ResMed Inc. is a leading global company in the healthcare sector, specializing in medical instruments and supplies for respiratory care. It is a dominant player in the sleep apnea treatment market, leveraging its core advantages in developing flow generators, masks, and digital health solutions.…
RMD
ResMed Inc.
$224.09
Investment Opinion: Should I buy RMD Today?
Based on a synthesis of the data, the objective assessment leans towards a 'Hold' with a view for accumulation on weakness. The fundamental case for long-term investment is strong, supported by excellent financials and a PEG ratio indicating undervaluation. However, the severe technical breakdown and negative momentum advise against immediate aggressive buying. The stock appears to be in a 'show me' state where it needs to demonstrate price stability and a break in the downtrend to confirm a bottom. Patient investors may find current levels attractive for initiating or adding to a position with a long-term horizon.
Sign up to view all
RMD 12-Month Price Forecast
The investment thesis is bifurcated. The fundamental engine of the company is powerful, but the stock's price action is broken. The current price offers a favorable risk/reward for long-term investors, but timing the entry is challenging due to clear negative momentum.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ResMed Inc.'s 12-month outlook, with a consensus price target around $291.32 and implied upside of +30.0% versus the current price.
Average Target
$291.32
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$179 - $291
Analyst target range
Wall Street analyst coverage for ResMed is active, with recent ratings from ten firms. The consensus sentiment appears mixed to cautiously optimistic. Recent actions include Citigroup and RBC Capital maintaining 'Buy' and 'Outperform' ratings, respectively, while Wells Fargo and Stifel maintain 'Equal Weight' and 'Hold' stances. Notably, Baird downgraded the stock from 'Outperform' to 'Neutral' in mid-December 2025. Analyst estimates project an average EPS of $16.20 and revenue of $7.79 billion for the upcoming period.
Bulls vs Bears: RMD Investment Factors
ResMed presents a classic conflict between strong, defensive fundamentals and a severely damaged technical picture. The company's financial health, market position, and growth prospects are compelling, but the stock is under intense selling pressure and sentiment is weak. The current price near 52-week lows may reflect an overreaction to broader market or sector concerns.
Bullish
- Strong Fundamentals: Robust revenue growth (11% YoY) and high profitability (27.6% net margin).
- Excellent Financial Health: Low debt (D/E 0.14), high liquidity (Current Ratio 3.44), strong cash flow.
- Attractive Valuation Metrics: Forward P/E of 18.4 and PEG ratio of 0.72 suggest undervaluation.
- Structural Market Growth: Sleep apnea market benefits from aging populations and rising obesity.
Bearish
- Severe Technical Downtrend: Stock down 18.9% over 6 months, significantly underperforming the market.
- Recent Sharp Sell-Off: Price fell 12.4% in the last month, breaking below key support levels.
- Mixed Analyst Sentiment: Recent downgrades (e.g., Baird) and holds signal near-term caution.
- High Short Interest: Short ratio of 11.77 indicates significant bearish speculative pressure.
RMD Technical Analysis
Overall Assessment: The stock has been in a pronounced downtrend over the past six months, declining 18.85% from its price in early October 2025. This performance significantly underperformed the broader market, as indicated by a -16.03 relative strength over six months. The trend shows a clear pattern of lower highs and lower lows, culminating in a recent sharp sell-off in March 2026.
Short-term Performance: Over the last month, the stock has fallen sharply by 12.40%, again underperforming the S&P 500 by 7.15 percentage points. The three-month performance is also negative at -6.80%, underperforming the market by 2.17 percentage points. The price data shows a steep decline from around $260 in late February to a low near $220 by the end of March.
Current Position: The current price of $224.48 is near the lower end of its 52-week range of $199.92 to $293.81, sitting approximately 12.4% above the 52-week low. The stock has recently rebounded slightly from its low of $220.03 on March 30th, but remains in a technically weak position following the recent breakdown.
Beta
0.89
0.89x market volatility
Max Drawdown
-25.1%
Largest decline past year
52-Week Range
$200-$294
Price range past year
Annual Return
+0.5%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -13.2% | -3.6% |
| 3m | -8.5% | -4.0% |
| 6m | -19.6% | -2.0% |
| 1y | +0.5% | +16.2% |
| ytd | -8.5% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
Revenue & Profitability: The company demonstrates solid revenue growth, with the latest quarterly revenue of $1.42 billion representing a 10.98% year-over-year increase. Profitability remains strong, with a net margin of 27.59% for the quarter ending December 2025, consistent with its trailing net margin of 27.22%. The operating margin for the quarter was a healthy 34.97%.
Financial Health: ResMed maintains a robust balance sheet with a low debt-to-equity ratio of 0.14, indicating minimal financial leverage. Liquidity is excellent, evidenced by a high current ratio of 3.44. The company generates substantial cash flow, with free cash flow over the trailing twelve months reported at $1.79 billion.
Operational Efficiency: The company exhibits strong returns, with a Return on Equity (ROE) of 23.47% and a Return on Assets (ROA) of 14.75%, indicating efficient use of shareholder capital and assets. The gross margin for the latest quarter was 62.18%, reflecting strong pricing power and cost management in its core operations.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Valuation Level: Given the company's consistent profitability with a positive net margin, the Price-to-Earnings (P/E) ratio is the primary valuation metric. The trailing P/E ratio is 27.02, while the forward P/E is lower at 18.43, suggesting expectations of earnings growth. The PEG ratio of 0.72, based on trailing metrics, indicates the stock may be undervalued relative to its growth prospects.
Peer Comparison: Data for direct industry average valuation multiples (e.g., average P/E for Medical Instruments) is not available in the provided inputs for a precise peer comparison. The valuation appears to be pricing in future growth, as reflected in the forward P/E being significantly lower than the trailing figure.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is the continuation of the technical downtrend, which could be driven by broader market weakness, sector rotation out of healthcare, or concerns over growth sustainability despite strong recent results. The high short interest (11.77) presents a near-term risk of amplified downward moves and volatility. While the balance sheet is robust, a prolonged downturn could pressure valuation multiples further, especially if forward earnings estimates are revised downward. Regulatory changes in healthcare reimbursement or increased competition in the sleep apnea device market are perennial industry risks, though not highlighted in recent data. The lack of positive news catalysts in the provided data leaves the stock vulnerable to negative sentiment prevailing.
FAQ
The key risks are technical and sentiment-driven. The stock is in a pronounced downtrend with high short interest (11.77), which can fuel further declines. There is also risk of valuation multiple compression if earnings growth slows. While not highlighted in recent data, standard industry risks include changes in healthcare regulation and reimbursement rates.
The 12-month outlook is mixed with a neutral base case. The base case (50% probability) sees a target range of $240-$270, aligning with forward earnings estimates. The bull case (30%) targets a return to the $280-$293 range on a fundamental re-rating, while the bear case (20%) could see a retest of the 52-week low near $200 if selling pressure persists.
Based on provided metrics, RMD appears undervalued relative to its growth. Its forward P/E of 18.4 is reasonable, and the PEG ratio of 0.72 (below 1.0) traditionally signals undervaluation. The trailing P/E of 27 is higher, but the discount in the forward multiple and low PEG suggest the market is not fully pricing in its growth prospects.
RMD is a good long-term investment candidate at current prices, but timing is tricky. The company's fundamentals are excellent with 11% revenue growth and a 27.6% net margin. However, the stock is in a severe downtrend, down 18.9% in six months. It is more suitable for patient, value-oriented investors willing to wait for a technical recovery.
RMD is far more suitable for long-term investment. Its strong market position, financial health, and structural tailwinds are long-duration assets. The current technical weakness makes it a poor candidate for short-term trading. Investors should have a horizon of 3-5 years to allow fundamentals to overcome near-term price volatility and sentiment.